Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, October 15, 2019

How Well Does Stroke Thrombectomy Work for Children?

Since they don't tell you how many 100% recovered I can only assume it was a complete failure in that regard. But their tyranny of low expectations was so fucking low they declared success anyway.  They all need to be shot. 

How Well Does Stroke Thrombectomy Work for Children?

Multicenter study suggests most recover with little disability

  • by Senior Associate Editor, MedPage Today
Stent retrievers and other endovascular thrombectomy treatments appeared as safe(but effective to 100% recovery?) for selected children as seen in adult trials, and also had good neurologic outcomes, in the Save ChildS Study.
Among 73 children treated at 27 centers in the U.S. and Europe, the most feared complication -- symptomatic intracerebral hemorrhage -- occurred in only one, for a 1.37% rate that was favorable compared with the 2.79% rate in the HERMES meta-analysis of adult trials.
No vascular complications, such as dissections or vessel rupture, were reported by Peter Sporns, MD, MHBA, of Universitätsklinikum Muenster in Germany, and colleagues in JAMA Neurology.
The only periprocedural complication was transient vasospasm on angiography in four patients (5%) that resolved without clinical sequelae. Malignant infarction followed by decompressive hemicraniectomy occurred in three children (4%). One patient with preexisting congenital heart disease died of cardiac arrest after complete recanalization.
"This study may support clinicians' practice of off-label thrombectomy in childhood stroke in the absence of high-level evidence," the researchers concluded.
Neurologic improvement also "showed a similar pattern as observed in the adult trials," as median Pediatric National Institutes of Health Stroke Scale (PedNIHSS) score improved from 14.0 at admission to 4.0 at day 7.
Median modified Rankin scale (mRS) score was 1.0 on the 6-point scale at both 6 and 24 months, with 80% having a favorable neurologic outcome (mRS ≤2) at discharge and more than 85% at the same point by 180 days.
None of the seven trials in the adult-trial meta-analysis reached much beyond 70% at 90 days on that measure.
However, an accompanying editorial expressed deep reservations about how much could be made of the findings, given the methods.
First, 24-month neurologic outcome data were missing for more than one-third of the children, "introducing the possibility of selection bias," wrote Christine Fox, MD, of the University of California San Francisco, and Nomazulu Dlamini, MBBS, PhD, of the Hospital for Sick Children in Toronto.
"Data for earlier outcomes were more complete, but because deficits may emerge over time in children, early outcomes may not provide the full picture," they wrote. "Cognitive and language deficits may initially go unrecognized in a toddler but become apparent as skills required for success in school grow increasingly complex."
And using historical data from the meta-analysis for comparison "has pitfalls," they added. "Given differences in the interpretation of outcome instruments and timing of outcome measures in the Save ChildS study compared with the HERMES trials, comparisons between these studies are of questionable value."
Clinical trials are unlikely to be done to support the guidelines suggesting mechanical thrombectomy with stent retrievers as reasonable to consider for some patients <18 years with large-vessel occlusion, Sporns' group noted.
The one trial that had started had to be abandoned for lack of recruitment.
Sporns' study included all patients ages ≤18 years diagnosed with arterial ischemic stroke who underwent endovascular recanalization from 2000 through 2018 at participating centers. Most treatment was with clot retrievers (82%), while distal thromboaspiration was used in 10%, along with a smattering of other tools. All patients immediately went to the pediatric ICU after endovascular treatment.
The researchers cautioned that, although all types of stroke sources were included, only seven patients had focal or bilateral cerebral arteriopathy. "Thus, an a priori selection bias of thrombectomy against children with potential inflammatory vasculopathy may be inherent to a seemingly low overall hemorrhagic risk," they wrote.
"Vascular fragility and risk of hemorrhage need to be considered and weighted carefully against a potential benefit of a recanalization treatment in this specific patient population," they noted. "Underlying abnormalities are often unknown at the time of admission; therefore, the emergency decision on whether to perform thrombectomy frequently has to be made without detailed knowledge about the cause of the stroke."
Sporns disclosed no relevant relationships with industry. Co-authors disclosed multiple relevant relationships with industry, including thrombectomy device makers, and holding relevant patents.
Fox and Dlamini disclosed no relevant relationships with industry.

No comments:

Post a Comment